scPharmaceuticals (SCPH) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary

Strategic focus and product overview

• Specializes in delivering hospital-grade drugs at home, targeting cardiorenal conditions with a commercial-stage product portfolio.

• Furoscix, a subcutaneous furosemide patch pump, launched mid-2022, generated $36.2 million in 2024 net revenue.

• Strong IP protection: infusor patent to 2035, auto-injector patent to 2040.

• Auto-injector submission planned for later this year, aiming to cut costs by 75%.

• Expanded label for Class IV heart failure approved in August; PDUFA date for chronic kidney disease indication is March 6.

Market opportunity and clinical impact

• Heart failure represents a $9.5 billion market with 4 million annual worsening events; Furoscix targets 2 million of these.

• Furoscix offers 99.6% bioavailability, matching IV diuresis, and can prevent up to 60% of heart failure admissions.

• Clinical studies show $17,000-$28,000 in healthcare cost savings and 37% reduction in hospitalizations.

• Class IV patients, about 10% of the population, drive higher script sizes and utilization.

• Chronic kidney disease indication could add 700,000 patients and $3 billion in addressable market.

Commercial execution and growth drivers

• Sales force expanded by 40% in late 2023, supporting 20-25% quarterly revenue growth.

• Medicare redesign reduces patient out-of-pocket costs from ~$4,000 to $2,000, improving access and adherence.

• IDN channel sales doubled from Q3 to Q4, with further growth expected.

• Auto-injector pivotal study met all endpoints; submission targeted for mid-year, with strong physician feedback.

• Marketing and KOL outreach underway for nephrology launch; first sales in nephrology expected in April.